What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Immune system
- Tuberculosis
The scientist’s investigation covers issues in Immunology, Tuberculosis, Mycobacterium tuberculosis, Virology and Immune system.
His Immunology study frequently intersects with other fields, such as Latent tuberculosis.
Willem A. Hanekom has researched Tuberculosis in several fields, including Internal medicine, Surgery and Vaccination.
His research integrates issues of Adverse effect, Clinical trial and Immunogenicity in his study of Vaccination.
His research in Mycobacterium tuberculosis intersects with topics in HLA-E, Asymptomatic, Gene, Seroconversion and Cohort.
Willem A. Hanekom interconnects Healthy volunteers and Antigen in the investigation of issues within Immune system.
His most cited work include:
- Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial (729 citations)
- A blood RNA signature for tuberculosis disease risk: a prospective cohort study. (397 citations)
- Immunological biomarkers of tuberculosis. (363 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Immunology, Tuberculosis, Mycobacterium tuberculosis, Vaccination and Immune system.
In his study, Interferon gamma is strongly linked to Virology, which falls under the umbrella field of Immunology.
His Tuberculosis study combines topics in areas such as Internal medicine, Clinical trial and Disease.
His Mycobacterium tuberculosis study deals with Tuberculin intersecting with QuantiFERON.
In his work, Randomized controlled trial is strongly intertwined with Immunogenicity, which is a subfield of Vaccination.
His Immune system research is multidisciplinary, incorporating elements of Tumor necrosis factor alpha, Mycobacterium bovis, Cytokine and Monocyte.
He most often published in these fields:
- Immunology (71.59%)
- Tuberculosis (64.77%)
- Mycobacterium tuberculosis (38.64%)
What were the highlights of his more recent work (between 2016-2021)?
- Tuberculosis (64.77%)
- Immunology (71.59%)
- Mycobacterium tuberculosis (38.64%)
In recent papers he was focusing on the following fields of study:
Tuberculosis, Immunology, Mycobacterium tuberculosis, Immune system and Vaccination are his primary areas of study.
His research on Tuberculosis focuses in particular on Tuberculosis vaccines.
His studies in Mycobacterium tuberculosis integrate themes in fields like Inflammation, BTLA, Coinfection and Virology.
He has included themes like Mycobacterium bovis, Gene knockdown and Monocyte in his Immune system study.
His Vaccination research integrates issues from Myeloid, Whole blood and Randomized controlled trial.
His study in T cell is interdisciplinary in nature, drawing from both Asymptomatic and CD8.
Between 2016 and 2021, his most popular works were:
- Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination (244 citations)
- Metabolite changes in blood predict the onset of tuberculosis (151 citations)
- Four-gene pan-African blood signature predicts progression to tuberculosis (105 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Immune system
- Disease
His primary areas of investigation include Tuberculosis, Mycobacterium tuberculosis, Immunology, Internal medicine and Vaccination.
His Tuberculosis research incorporates elements of Disease and Cohort.
His study in Immune system, Antigen and T cell are all subfields of Immunology.
Willem A. Hanekom combines subjects such as Myeloid, Whole blood and Inflammation with his study of Immune system.
His biological study deals with issues like Placebo, which deal with fields such as Dose selection and Adverse effect.
His studies deal with areas such as Reprogramming, Innate immune system, Bone marrow and Immunity as well as Vaccination.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
